Freddie Ann Hoffman

Summary

Affiliation: LLC NA
Country: USA

Publications

  1. ncbi Comments on public health concerns: facts, fiction and gaps in knowledge
    Freddie Ann Hoffman
    HeteroGeneity, LLC NA, Washington, DC, USA
    Thromb Res 117:177-84; discussion 201-7. 2005
  2. ncbi Comments on public health concerns: facts, fiction, and gaps in knowledge
    Freddie Ann Hoffman
    HeteroGeneity, LLC, Washington, DC, USA
    Thromb Res 117:177-8; discussion 201-7. 2005
  3. ncbi Development of probiotics as biologic drugs
    Freddie Ann Hoffman
    HeteroGeneity, Washington, DC 20011, USA
    Clin Infect Dis 46:S125-7; discussion S144-51. 2008
  4. ncbi Business considerations in the development of probiotics
    Freddie Ann Hoffman
    HeteroGeneity, Washington, DC 20011, USA
    Clin Infect Dis 46:S141-3; discussion S144-51. 2008
  5. ncbi Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs
    Freddie Ann Hoffman
    HeteroGeneity, Washington, DC 20011, USA
    Clin Infect Dis 46:S53-7. 2008

Detail Information

Publications5

  1. ncbi Comments on public health concerns: facts, fiction and gaps in knowledge
    Freddie Ann Hoffman
    HeteroGeneity, LLC NA, Washington, DC, USA
    Thromb Res 117:177-84; discussion 201-7. 2005
  2. ncbi Comments on public health concerns: facts, fiction, and gaps in knowledge
    Freddie Ann Hoffman
    HeteroGeneity, LLC, Washington, DC, USA
    Thromb Res 117:177-8; discussion 201-7. 2005
  3. ncbi Development of probiotics as biologic drugs
    Freddie Ann Hoffman
    HeteroGeneity, Washington, DC 20011, USA
    Clin Infect Dis 46:S125-7; discussion S144-51. 2008
    ..This article provides a brief overview of the historical basis of US regulation of drugs and biologics and explores the legal, regulatory, and policy considerations for probiotics as biologic drugs for humans...
  4. ncbi Business considerations in the development of probiotics
    Freddie Ann Hoffman
    HeteroGeneity, Washington, DC 20011, USA
    Clin Infect Dis 46:S141-3; discussion S144-51. 2008
    ..This article discusses many of the elements that should be considered in the decision to market probiotics as foods, dietary supplements, or drugs...
  5. ncbi Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs
    Freddie Ann Hoffman
    HeteroGeneity, Washington, DC 20011, USA
    Clin Infect Dis 46:S53-7. 2008